• Licette C Y Liu, Elise Schutte, Ron T Gansevoort, Peter van der Meer, and Adriaan A Voors.
• University of Groningen, University Medical Center Groningen, Department of Cardiology , Groningen , The Netherlands.
• Expert Opin Investig Drugs. 2015 Jan 1; 24 (8): 1123-35.

IntroductionThe mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone reduce the risk of hospitalizations and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), and attenuate progression of diabetic kidney disease. However, their use is limited by the fear of inducing hyperkalemia, especially in patients with renal dysfunction. Finerenone is a novel nonsteroidal MRA, with higher selectivity toward the mineralocorticoid receptor (MR) compared to spironolactone and stronger MR-binding affinity than eplerenone.Areas CoveredThis paper discusses the chemistry, pharmacokinetics, clinical efficacy and safety of finerenone.Expert OpinionThe selectivity and greater binding affinity of finerenone to the MR may reduce the risk of hyperkalemia and renal dysfunction and thereby overcome the reluctance to start and uptitrate MRAs in patients with HF and diabetic kidney disease. Studies conducted in patients with HFrEF and moderate chronic kidney disease and diabetic kidney disease, showed promising results. Phase III trials will have to show whether finerenone might become the third-generation MRA for the treatment of HF and diabetic kidney disease.

17 keywords...

hide…